This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rowe, P. S.N. Search for Related Content PubMed PubMed Citation Social Bookmarking                         What's this?

THE WRICKKENED PATHWAYS OF FGF23, MEPE AND PHEX

Department of Periodontics, The University of Texas Health Science Center at San Antonio, Mail Code 7894, 7703 Floyd Curl Drive, Room 3.579U, San Antonio, TX 78229-3900, USA; rowep{at}uthscsa.edu

The last 350 years since the publication of the first medical monograph on rickets (old English term wrickken) (Glisson et al., 1651) have seen spectacular advances in our understanding of mineral-homeostasis. Seminal and exciting discoveries have revealed the roles of PTH, vitamin D, and calcitonin in regulating calcium and phosphate, and maintaining healthy teeth and skeleton. However, it is clear that the PTH/Vitamin D axis does not account for the entire picture, and a new bone-renal metabolic milieu has emerged, implicating a novel set of matrix proteins, hormones, and Zn-metallopeptidases. The primary defects in X-linked hypophosphatemic rickets (HYP) and autosomal-dominant hypophosphatemic rickets (ADHR) are now identified as inactivating mutations in a Zn-metalloendopeptidase (PHEX) and activating mutations in fibroblast-growth-factor-23 (FGF23), respectively. In oncogenic hypophosphatemic osteomalacia (OHO), several tumor-expressed proteins (MEPE, FGF23, and FRP-4) have emerged as candidate mediators of the bone-renal pathophysiology. This has stimulated the proposal of a global model that takes into account the remarkable similarities between the inherited diseases (HYP and ADHR) and the tumor-acquired disease OHO. In HYP, loss of PHEX function is proposed to result in an increase in uncleaved full-length FGF23 and/or inappropriate processing of MEPE. In ADHR, a mutation in FGF23 results in resistance to proteolysis by PHEX or other proteases and an increase in half-life of full-length phosphaturic FGF23. In OHO, over-expression of FGF23 and/or MEPE is proposed to result in abnormal renal-phosphate handling and mineralization. Although this model is attractive, many questions remain unanswered, suggesting a more complex picture. The following review will present a global hypothesis that attempts to explain the experimental and clinical observations in HYP, ADHR, and OHO, plus diverse mouse models that include the MEPE null mutant, HYP-PHEX transgenic mouse, and MEPE-PHEX double-null-mutant.

Key Words: PHEX • MEPE • FGF23 • mineralization • hypophosphatemia • phosphaturic • osteomalacia • rickets

Critical Reviews in Oral Biology & Medicine, Vol. 15, No. 5, 264-281 (2004)
DOI: 10.1177/154411130401500503


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. S. Levine, C. R. Kleeman, and A. J. Felsenfeld The Journey From Vitamin D-Resistant Rickets to the Regulation of Renal Phosphate Transport Clin. J. Am. Soc. Nephrol., November 1, 2009; 4(11): 1866 - 1877. [Abstract] [Full Text] [PDF]

				Y.-D. Cho, W.-J. Yoon, K.-M. Woo, J.-H. Baek, G. Lee, J.-Y. Cho, and H.-M. Ryoo Molecular Regulation of Matrix Extracellular Phosphoglycoprotein Expression by Bone Morphogenetic Protein-2 J. Biol. Chem., September 11, 2009; 284(37): 25230 - 25240. [Abstract] [Full Text] [PDF]

				V. David, A. Martin, A.-M. Hedge, and P. S. N. Rowe Matrix Extracellular Phosphoglycoprotein (MEPE) Is a New Bone Renal Hormone and Vascularization Modulator Endocrinology, September 1, 2009; 150(9): 4012 - 4023. [Abstract] [Full Text] [PDF]

				J. Marks, L. J. Churchill, E. S. Debnam, and R. J. Unwin Matrix Extracellular Phosphoglycoprotein Inhibits Phosphate Transport J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2313 - 2320. [Abstract] [Full Text] [PDF]

				A. Martin, V. David, J. S. Laurence, P. M. Schwarz, E. M. Lafer, A.-M. Hedge, and P. S. N. Rowe Degradation of MEPE, DMP1, and Release of SIBLING ASARM-Peptides (Minhibins): ASARM-Peptide(s) Are Directly Responsible for Defective Mineralization in HYP Endocrinology, April 1, 2008; 149(4): 1757 - 1772. [Abstract] [Full Text] [PDF]

				H. Dobbie, R. J. Unwin, N. J. R. Faria, and D. G. Shirley Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption Nephrol. Dial. Transplant., February 1, 2008; 23(2): 730 - 733. [Abstract] [Full Text] [PDF]

				C. Qin, R. D'Souza, and J.Q. Feng Dentin Matrix Protein 1 (DMP1): New and Important Roles for Biomineralization and Phosphate Homeostasis Journal of Dental Research, December 1, 2007; 86(12): 1134 - 1141. [Abstract] [Full Text] [PDF]

				C. Silve DMP1 and Phosphate Metabolism - Matrix Proteins Go Systemic IBMS BoneKEy, December 1, 2006; 3(12): 30 - 35. [Full Text] [PDF]